Effect of direct thrombin inhibitors, bivalirudin, lepirudin, and argatroban, on prothrombin time and INR values

被引:74
|
作者
Gosselin, RC
Dager, WE
King, JH
Janatpour, K
Mahackian, K
Larkin, EC
Owings, JT
机构
[1] Univ Calif Davis, Med Ctr, Dept Surg, Trauma Div, Sacramento, CA 95817 USA
[2] Univ Calif Davis, Med Ctr, Dept Pharm, Sacramento, CA 95817 USA
[3] Univ Calif Davis, Med Ctr, Dept Pathol, Sacramento, CA 95817 USA
关键词
direct thrombin inhibitors; prothrombin time; international normalized ratio; INR; argatroban; bivalirudin; lepirudin;
D O I
10.1309/D79K4YG78NTNYY38
中图分类号
R36 [病理学];
学科分类号
100104 ;
摘要
Direct thrombin inhibitors (DTIs) represent a new class of promising anticoagulation agents. The DTIs frequently are used to provide initial anticoagulation, with long-term therapy requiring eventual transition to coumarins. Unfortunately, DT's not only prolong the activated partial thromboplastin time but also can affect international normalized ratio (INR) values. We approximated the DTI effect on INRs by each drug to pooled plasma at concentrations between 0.1 and 1.2,mug/mL. We then concurrently tested these samples using 14 prothrombin time (PT) reagents. By using repeated measures analysis of variance, we found significant differences (P <.05) between the median INRs for lepirudin and argatroban for all PT reagents, between lepirudin and bivalirudin for all reagents except PT-Fibrinogen HS Plus (P = .07), and between bivalirudin and argatroban for all reagents except Thromborel S (P = .05). The DTI effect on INRs was dependent on drug, drug concentration, and reagent. Argatroban had the most effect on INRs, while lepirudin had the least effect. Reagents with a lower international sensitivity index were less affected by DTI; ThromboMax HS was the least sensitive PT reagent to any DTI.
引用
收藏
页码:593 / 599
页数:7
相关论文
共 20 条
  • [2] Differences in the clinically effective molar concentrations of four direct thrombin inhibitors explain their variable prothrombin time prolongation
    Warkentin, TE
    Greinacher, A
    Craven, S
    Dewar, L
    Sheppard, JAI
    Ofosu, FA
    THROMBOSIS AND HAEMOSTASIS, 2005, 94 (05) : 958 - 964
  • [3] Direct inhibitors of thrombin, hirudin, bivalirudin, and dabigatran etexilate
    Meddahi, S.
    Samama, M. M.
    JOURNAL DES MALADIES VASCULAIRES, 2011, 36 (01) : 24 - 32
  • [4] The Anti-Inflammatory Effects of Argatroban Can Be Differentiated from Other Direct Thrombin Inhibitors: Experimental and Clinical Observations
    Hoppensteadt, Debra A.
    Jeske, Walter
    Walenga, Jeanine M.
    Bick, Rodger L.
    Fareed, Jawed
    SEMINARS IN THROMBOSIS AND HEMOSTASIS, 2008, 34 : 97 - 102
  • [5] The Direct Thrombin Inhibitors Dabigatran and Lepirudin Inhibit GPIbα-Mediated Platelet Aggregation
    Trabold, Katharina
    Makhoul, Stephanie
    Garnbaryan, Stepan
    van Ryn, Joanne
    Walter, Ulrich
    Jurk, Kerstin
    THROMBOSIS AND HAEMOSTASIS, 2019, 119 (06) : 916 - 929
  • [6] Clinically relevant differences in prothrombin time and INR values related to blood sample collection in plastic vs glass tubes
    Fiebig, EW
    Etzell, JE
    Ng, VL
    AMERICAN JOURNAL OF CLINICAL PATHOLOGY, 2005, 124 (06) : 902 - 909
  • [7] Novel uses for current and future direct thrombin inhibitors: focus on ximelagatran and bivalirudin
    Kalus, JS
    Caron, NF
    EXPERT OPINION ON INVESTIGATIONAL DRUGS, 2004, 13 (05) : 465 - 477
  • [8] Monitoring direct thrombin inhibitors with a plasma diluted thrombin time
    Love, Jason E.
    Ferrell, Chris
    Chandler, Wayne L.
    THROMBOSIS AND HAEMOSTASIS, 2007, 98 (01) : 234 - 242
  • [9] Limitation of the activated partial thromboplastin time as a monitoring method of the direct thrombin inhibitor argatroban
    Guy, S.
    Kitchen, S.
    Maclean, R.
    Van Veen, J. J.
    INTERNATIONAL JOURNAL OF LABORATORY HEMATOLOGY, 2015, 37 (06) : 834 - 843
  • [10] Monitoring Direct Thrombin Inhibitors With Calibrated Diluted Thrombin Time vs Activated Partial Thromboplastin Time in Pediatric Patients
    Hasan, Rida A.
    Pak, Jennifer
    Kirk, Christa Jefferis
    Friedland-Little, Joshua M.
    Chandler, Wayne L.
    AMERICAN JOURNAL OF CLINICAL PATHOLOGY, 2023, 159 (01) : 60 - 68